West Nile fever

Summary

West Nile fever (MONDO:0002282) is a disease and 9 clinical trials. Top therapeutic interventions include sodium chloride and mgawn1. A subtype of Flaviviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	West Nile fever
Mondo ID	MONDO:0002282
MeSH	D014901
DOID	DOID:2366
ICD-10-CM	A92.3
SNOMED CT	417093003
UMLS	C0043124
MedGen	22705
Is cancer (heuristic)	no

Also known as: West Nile virus caused disease or disorder · West Nile virus disease or disorder · West Nile virus infectious disease

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Flaviviridae infectious disease › West Nile fever

Related subtypes (9): Powassan encephalitis, Murray valley encephalitis, dengue disease, pestivirus infectious disease, st. Louis encephalitis, Kyasanur forest disease, Omsk hemorrhagic fever, Zika virus infectious disease, yellow fever

Subtypes (1): West-Nile encephalitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Sodium Chloride	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
PHASE1	4
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07094724	PHASE2	RECRUITING	High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients
NCT00442169	PHASE2	COMPLETED	Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
NCT00746798	PHASE2	COMPLETED	Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
NCT00927953	PHASE2	TERMINATED	Treatment of West Nile Virus With MGAWN1
NCT00091845	PHASE1	TERMINATED	An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease
NCT00106769	PHASE1	COMPLETED	Vaccine to Prevent West Nile Virus Disease
NCT00300417	PHASE1	COMPLETED	Phase I Study of West Nile Virus Vaccine
NCT00537147	PHASE1	COMPLETED	Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults
NCT04371003	Not specified	WITHDRAWN	Prospective Investigation of Oxidative Stress in West Nile Virus Infection

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SODIUM CHLORIDE	4	1
MGAWN1	2	1